TRAVERE THERAPEUTICS, INC. Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
TRAVERE THERAPEUTICS, INC. (TVTX) reported Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation of $2.42 million for the 12-month period ending 2015-12-31, per its 10-K filed 2018-07-06.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation · last filed 2018-07-06
- TRAVERE THERAPEUTICS, INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2015 was $2.42M.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month |
|---|---|
| 2015-12-31 | $2.42M 10-K · filed 2018-07-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |